Liver transplant assessment for hepatocellular carcinoma: a single-centre experience

The authors aimed to analyze the assessment and acceptance rates for liver transplantation in patients with hepatocellular carcinoma (HCC) at a tertiary liver center, as well as to identify reasons for non-listing and the impact of the COVID-19 pandemic on these outcomes. They found that 64% of patients were accepted for listing, with medical comorbidities and rapid tumor progression being the primary reasons for non-listing. Additionally, the study highlighted a significant increase in dropout rates during the pandemic, underscoring the adverse effects of reduced transplant activity on HCC patients.